Sign in

CIK 0001690585 · Non-accelerated filer<br>Smaller reporting company

Dianthus Therapeutics, Inc. /DE/

Sign in to watch
Ticker
DNTH
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
DE
Entity type
operating
Phone
929-999-4055
Business address
7 TIMES SQUARE, 43RD FLOOR, NEW YORK, NY, 10036
Former names
Magenta Therapeutics, Inc.
Open-market buys, last 90 days
$0
in 0 filings
Open-market sales, last 90 days
$16,043,610
in 4 filings, $16.0M under 10b5-1 plans

Net −$16,043,610. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.

Pace of trading Bought Sold

Who's trading

90 days

  1. Savitz Ryan −$11.2M EVP, CFO & CBO sold 100% of stake
  2. Randhawa Simrat −$2.5M EVP, Head of R&D sold 85% of stake
  3. CARR EDWARD −$2.0M CHIEF ACCOUNTING OFFICER sold 100% of stake
  4. Read Simon −$327K Director sold 100% of stake
Date Insider Transaction Shares Price Value Owned after
2018-06-25 Atlas Venture Fund X, L.P. 10% owner Conversion · Series B Preferred Stock −204,339 0
2018-06-25 Scadden David Director Conversion +28,076 221,575
2018-06-25 Scadden David Director Purchase +6,600 $15.00 $99K 228,175
2018-06-25 Scadden David Director Conversion · Series A Preferred Stock −50,025 0
2018-06-25 Scadden David Director Conversion · Series B Preferred Stock −6,429 0
2018-06-25 Scadden David Director Conversion · Series C Preferred Stock −16,094 0
2018-06-25 Third Rock Ventures IV, L.P. 10% owner Conversion +7,911,455 8,008,204
2018-06-25 Third Rock Ventures IV, L.P. 10% owner Conversion · Series A Preferred Stock −20,102,478 0
2018-06-25 Third Rock Ventures IV, L.P. 10% owner Conversion · Series B Preferred Stock −340,566 0
2018-06-25 Daniel Thomas O Director Conversion +24,527 101,926
2018-06-25 Daniel Thomas O Director Conversion · Series A Preferred Stock −33,350 0
2018-06-25 Daniel Thomas O Director Conversion · Series B Preferred Stock −30,028 0
2018-06-25 RONNEBERG AMY L Director Conversion +593,611 593,611
2018-06-25 RONNEBERG AMY L Director Conversion · Series B Preferred Stock −1,287,100 0
2018-06-25 RONNEBERG AMY L Director Conversion · Series C Preferred Stock −246,781 0
2018-06-25 COOKE MICHAEL P. Chief Scientific Officer Conversion +4,370 293,023
2018-06-25 COOKE MICHAEL P. Chief Scientific Officer Conversion · Series A Preferred Stock −10,005 0
2018-06-25 COOKE MICHAEL P. Chief Scientific Officer Conversion · Series B Preferred Stock −1,287 0
2018-06-25 ZDRAVESKI ZORAN See Remarks Conversion +4,643 140,092
2018-06-25 ZDRAVESKI ZORAN See Remarks Conversion · Series C Preferred Stock −12,000 0

Page 22 of 24 · 470 trades